The recent discovery of an acquired activating point mutation in JAK2, substituting valine at
amino acid position 617 for phenylalanine, has greatly improved our understanding of the …

Owing to the prevalence of the JAK2V617F mutation in myeloproliferative neoplasms
(MPNs), its constitutive activity, and ability to recapitulate the MPN phenotype in mouse …

Background: A mutation in the Janus tyrosine kinase 2 gene (JAK2 V617F) has been
recognized in Philadelphia chromosome-negative myeloproliferative disorders, including PV …

Purpose: The discovery of an activating somatic mutation in codon 617 of the gene encoding
the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has …

The recent identification of somatic mutations such as JAK2V617F that deregulate Janus
kinase (JAK)–signal transducer and activator of transcription signaling has spurred …

The discovery of the Janus kinase (JAK) 2 V617F mutation in patients with myeloproliferative
neoplasms was a major milestone in understanding the biology of those disorders. Several …

Background: The recent discovery of JAK2V617F, as an activating mutation in the majority of
patients with myeloproliferative neoplasms, has spurred development of JAK2-selective …

The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with
myeloproliferative neoplasms and leukemias. Due to their involvement in neoplasia and …

Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates
myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a …

Activating mutations in Janus kinase 2 (JAK2) have recently been identified in the majority of
Philadelphia chromosome negative (Ph-) myeloproliferative disorders (MPDs). Importantly …